Clinical CBD phenotypes and features were combined to create two sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based diseases [17▪]. The gene discussed is MAPT; the disease is red-green color blindness.